Cargando…
Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
INTRODUCTION: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies. This approval was based on evidence from FAME trials which were conducted at a time when r...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700741/ https://www.ncbi.nlm.nih.gov/pubmed/26728265 http://dx.doi.org/10.1186/s12886-015-0178-9 |